Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 18/20 | 0.47 |
| ▸ | CCND1 | P24385 | 18/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 12/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.45 |
| ▸ | CDK2 | P24941 | 12/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122461 | 0.86 | CDK4 (0.51) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7963215 | 0.77 | CDK4 (0.46) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL8112963 | 0.77 | CDK4 (0.45) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7962973 | 0.76 | CDK4 (0.49) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7446420 | 0.76 | CDK4 (0.49) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7964095 | 0.73 | CDK4 (0.47) | CDK4CCND1CRHR1 | |
| SCHEMBL7953100 | 0.73 | CDK4 (0.63) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL7964093 | 0.73 | CDK4 (0.51) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5707841 | 0.72 | CDK4 (0.46) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL5600331 | 0.71 | CDK4 (0.53) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218397-B1 | FOR THERAPY OF STRESS-RELATED ILLNESSES, SUCH AS STRESS-INDUCED DEPRESSION, ANXIETY, AND HEADACHE; ABDOMINAL BOWEL SYNDROME; INFLAMMATORY DISEASES; IMMUNE SUPPRESSION; ALZHEIMER'S DISEASE; GASTRONINTESTINAL DISEASES | PFIZER INC | 2001-04-17 | — | — | US | disclosed |
| EP-0674642-B1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0674642-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013677-A1 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |